Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Candida auris, a multidrug-resistant yeast that causes invasive infections, was first described in 2009 in Japan and has since been reported from several countries. METHODS: To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012-2015 and the type specimen from Japan. Patient information was available for 41 of the isolates. We conducted antifungal susceptibility testing and whole-genome sequencing (WGS). RESULTS: Available clinical information revealed that 41% of patients had diabetes mellitus, 51% had undergone recent surgery, 73% had a central venous catheter, and 41% were receiving systemic antifungal therapy when C. auris was isolated. The median time from admission to infection was 19 days (interquartile range, 9-36 days), 61% of patients had bloodstream infection, and 59% died. Using stringent break points, 93% of isolates were resistant to fluconazole, 35% to amphotericin B, and 7% to echinocandins; 41% were resistant to 2 antifungal classes and 4% were resistant to 3 classes. WGS demonstrated that isolates were grouped into unique clades by geographic region. Clades were separated by thousands of single-nucleotide polymorphisms, but within each clade isolates were clonal. Different mutations in ERG11 were associated with azole resistance in each geographic clade. CONCLUSIONS: C. auris is an emerging healthcare-associated pathogen associated with high mortality. Treatment options are limited, due to antifungal resistance. WGS analysis suggests nearly simultaneous, and recent, independent emergence of different clonal populations on 3 continents. Risk factors and transmission mechanisms need to be elucidated to guide control measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“C. auris, a novel Candida species first identified in 2009, has emerged since 2013 as a cause of nosocomial outbreaks in multiple countries across 5 continents.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [16]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to all three classes of antifungals is reported most commonly in India in South Asia (3%), whereas this is much less common in other regions of the world.122–124”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [122]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Invasive C. auris infections are associated with high mortality rates, with 60% of hospitalizations due to C. auris infections resulting in death (8).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three such mutations, encoding the amino acid substitutions VF125AL (commonly referred to as F126L), Y132F, and K143R, are frequently reported among fluconazole-resistant clinical isolates, and associations between these mutations and specific genetic clades of C. auris have been observed (2).”
From Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, up to 96% of C. auris may exhibit resistance to fluconazole, an exceptionally high value compared to 0.5–2% for C. albicans, 4–9% for C. tropicalis, 2–6% for C. parapsilosis, and 11–13% for C. glabrata [16,40,41].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [16]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0
Tamura, K., Stecher, G., Peterson, D., Filipski, A., & Kumar, S. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst197 · Cited by 47,205
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · cited 1×
“SNPs were identified using 2 independent pipelines, as described elsewhere (see also the legend to Supplemental Figure 1) [15, 19].”
MethodEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“auris because we did not have a comparison group of patients with other Candida infections from the same institutions [31].”
BackgroundResultNonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data
Chin, C.-S., Alexander, D. H., Marks, P., Klammer, A. A., Drake, J., Heiner, C., Clum, A., Copeland, A., Huddleston, J., Eichler, E. E., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2474 · Cited by 4,029 · cited 1×
“The reference genome was generated by de novo assembly of PacBio reads from isolate B8441, as described elsewhere [18], and used as a reference for single-nucleotide polymorphism (SNP) calling.”
MethodSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381 · cited 8×
“To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012–2015 and the type specimen from Japan.”
BackgroundInfluentialEvolution of pathogenicity and sexual reproduction in eight Candida genomes
Butler, G., Rasmussen, M. D., Lin, M. F., Santos, M. A. S., Sakthikumar, S., Munro, C. A., Rheinbay, E., Grabherr, M., Forche, A., Reedy, J. L., et al. (2009) · Nature · doi:10.1038/nature08064 · Cited by 1,065 · cited 1×
“5 Mb, similar to that of other Candida species [25].”
BackgroundSelf-citationKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 1×
“It phenotypically resembles Candida haemulonii and requires use of molecular methods for identification [9, 10].”
MethodSelf-citationFirst Three Reported Cases of Nosocomial Fungemia Caused by Candida auris
Lee, W. G., Shin, J. H., Uh, Y., Kang, M. G., Kim, S. H., Park, K. H., & Jang, H.-C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00319-11 · Cited by 523 · cited 2×
“auris [3], establishing that this new species was capable of causing invasive infections.”
BackgroundPerea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454 · cited 1×
“auris may become widely established within certain regions, as evidenced by the fact that it now accounts for nearly 5% of candidemia in Indian intensive care units [5].”
Background
Cited by
Items 701–800 of 1,007
Program, C. N. I. S. (2023) · Canada Communicable Disease Report · doi:10.14745/ccdr.v49i05a09 · Cited by 28
“Candida auris has been associated with outbreaks in healthcare settings in many countries, including Canada and the United States (55–58), and can cause both superficial and invasive infections with mortality ranging from 30%–60% (59).”
BackgroundWeber, D. J., Rutala, W. A., & Sickbert-Bennett, E. E. (2023) · American Journal of Infection Control · doi:10.1016/j.ajic.2023.02.006 · Cited by 22
Misas, E., Escandón, P., Gade, L., Cáceres, D. H., Hurst, S., Le, N., Min, B., Lyman, M., Duarte, C., & Chow, N. A. (2024) · mSphere · doi:10.1128/msphere.00577-23 · Cited by 23
Dighe, K., Moitra, P., Saha, P., Gunaseelan, N., & Pan, D. (2024) · Materials Today · doi:10.1016/j.mattod.2024.09.017 · Cited by 22
Dunne, W. M., Pouseele, H., Monecke, S., Ehricht, R., & van Belkum, A. (2017) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2017.09.019 · Cited by 21
First case of Candida auris infection in Belgium in a surgical patient from Kuwait
Dewaele, K., Frans, J., Smismans, A., Ho, E., Tollens, T., & Lagrou, K. (2018) · Acta Clinica Belgica · doi:10.1080/17843286.2018.1555114 · Cited by 27
“candidemia isolates from 2004 to 2015, collected in medical centers in Asia, Europe, South America and North America [22].”
BackgroundInfluentialInvasive fungal infection in crtically ill patients: hurdles and next challenges
Peral, J. M. A., Álvarez-Lerma, F., Maseda, E., Olaechea, P., Pemán, J., Soriano, C., & Zaragoza, R. (2019) · Journal of Chemotherapy · doi:10.1080/1120009x.2018.1557799 · Cited by 25
Kubiczek, D. H., Flaig, C., Raber, H. F., Dietz, S., Kissmann, A., Heerde, T., Bodenberger, N. E., Wittgens, A., González-García, M., Kang, F., et al. (2020) · Macromolecular Bioscience · doi:10.1002/mabi.202000005 · Cited by 22
Free‐living amoebae promote Candida auris survival and proliferation in water
Hubert, F., Rodier, M., Minoza, A., Sulla, V. P., Cateau, E., & Brunet, K. (2020) · Letters in Applied Microbiology · doi:10.1111/lam.13395 · Cited by 22
“One of the issues with C. auris is its ability to resist antifungal drugs (Lockhart et al. 2017).”
BackgroundCandida auris: The Canary in the Mine of Antifungal Drug Resistance
Montoya, M. C., Moye-Rowley, W. S., & Krysan, D. J. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00239 · Cited by 21
Yeoh, S. F., Lee, T. J., Chew, K. L., Lin, S., Yeo, D., & Setia, S. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s165676 · Cited by 20
“auris, which is resistant to multiple classes of drugs including echinocandins.(55) In a recent retrospective study of candidemia and IAC in patients with liver cirrhosis, higher mortality rates were associated with C.”
BackgroundUme6-dependent pathways of morphogenesis and biofilm formation in Candida auris
Louvet, M., Li, J., Brandalise, D., Bachmann, D., Sala de Oyanguren, F., Labes, D., Jacquier, N., Genoud, C., Mucciolo, A., Coste, A. T., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01531-24 · Cited by 20
Tan, C., Wu, A., & Li, C. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.102947 · Cited by 22
The Second Candida auris Isolate from Aural Discharge in Japan
Iguchi, S., Mizushima, R., Kamada, K., Itakura, Y., Yoshida, A., Uzawa, Y., Arai, Y. O., Takaoka, M., Sato, S., Goto, A., et al. (2018) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2017.466 · Cited by 22
Cellular and Extracellular Vesicle RNA Analysis in the Global Threat Fungus Candida auris
da Rocha, I. F. M., Martins, S. T., Amatuzzi, R. F., Zamith‐Miranda, D., Nosanchuk, J. D., Rodrigues, M. L., & Alves, L. R. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01538-21 · Cited by 20
Eradication of Fungi Using MoSe2/Chitosan Nanosheets
Saha, S., Gilliam, M. S., Wang, Q. H., & Green, A. A. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c01013 · Cited by 20
Modeling Candida auris skin colonization: Mice, swine, and humans
Eix, E. F., & Nett, J. E. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010730 · Cited by 21
“WhatAU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly: is Candida auris skin colonization? The recently emergent fungal pathogen Candida auris frequently persists on skin of patients and can cause invasive disease with mortality rates over 50% [1,2].”
BackgroundSasoni, N., Maidana, M., Rapela, M. G. L., Morales-López, S. E., Berrío, I., Gamarra, S. P., & García‐Effrón, G. (2022) · Medical Mycology · doi:10.1093/mmy/myac062 · Cited by 21
Al-Dossary, H. A., Rehman, S., Jermy, B. R., AlJindan, R. Y., Aldayel, A., AbdulAzeez, S., Akhtar, S., Khan, F. A., Borgio, J. F., & Al-Suhaimi, E. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102251 · Cited by 20
“Mostly, (encoding K143R) mutations were highly geographic associ ed with India and Pakistan clades [41].”
BackgroundКольцов, И. П., Strelnikova, N. V., Vitko, E. V., Vitko, L. G., & Savlyuk, O. E. (2023) · Pacific Medical Journal · doi:10.34215/1609-1175-2023-1-19-26 · Cited by 22
Bappy, M. N. I., Robin, T. B., Prome, A. A., Patil, R. B., Moin, A. T., Akter, R., Laskar, F. S., Roy, A., Akter, H., & Zinnah, K. M. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17026 · Cited by 23
Lee, E. H., Choi, M. H., Lee, K. H., Kim, D., Jeong, S. H., Song, Y. G., & Han, S. H. (2023) · Journal of Hospital Infection · doi:10.1016/j.jhin.2023.10.017 · Cited by 21
Rosa, R. M., Jiménez, A., Andrews, D. M., Dinh, H., Parra, K., Martínez, O., & Abbo, L. M. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad567 · Cited by 25
“Candida auris is a multidrug-resistant fungus that has rapidly spread worldwide [1].”
BackgroundNectriatide, a Potentiator of Amphotericin B Activity from Nectriaceae sp. BF-0114
Fukuda, T., Nagai, K., Yagi, A., Kobayashi, K., Uchida, R., Yasuhara, T., & Tomoda, H. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.8b01056 · Cited by 21
Multilocus sequence typing of azole-resistant Candida auris strains, South Africa
Magobo, R. E., Mhlanga, M., Corcoran, C., & Govender, N. P. (2020) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v35i1.116 · Cited by 22
Self-citationLarkin, P. M. K., Multani, A., Beaird, O. E., Dayo, A. J., Fishbein, G. A., & Yang, S. (2020) · Journal of Fungi · doi:10.3390/jof6030106 · Cited by 23
Lima, S. L., Rossato, L. L., & Melo, A. S. D. A. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104461 · Cited by 20
Raber, H. F., Sejfijaj, J., Kissmann, A., Wittgens, A., González-García, M., Alba, A., Vázquez, A. A., Morales-Vicente, F., Perez‐Erviti, J. A., Kubiczek, D. H., et al. (2021) · Pathogens · doi:10.3390/pathogens10040496 · Cited by 21
“auris can cause severe bloodstream infections in hospitalized patients and can lead to remarkably high mortalities between 35% and 60% [20,21].”
BackgroundAn overview of current and emerging antifungal pharmacotherapy for invasive fungal infections
Mueller, S. W., Kedzior, S. K., Miller, M. A., Reynolds, P., Kiser, T. H., Kršák, M., & Molina, K. C. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1892075 · Cited by 22
“4% of the isolates have been resistant to the three aforementioned drug classes [22,27].”
BackgroundOh, S.-H., Schliep, K. P., Isenhower, A., Rodriguez-Bobadilla, R., Vuong, V. M., Fields, C. J., Hernandez, A. G., & Hoyer, L. L. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.794529 · Cited by 22
The first invasive Candida auris infection in Taiwan
Tsai, Y.-T., Lu, P., Tang, H.-J., Huang, C., Hung, W., Tseng, Y.-T., Lee, K.-M., & Lin, S. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2100280 · Cited by 21
Cha, H., Won, D., & Bahn, Y.-S. (2025) · mBio · doi:10.1128/mbio.02475-23 · Cited by 19
Sarvestani, H. K., Mahmoudi, S., Khaki, P. A., Ansari, S., Ghaderkhani, S., Roostaei, D., Ghazvini, R. D., Hashemi, S. J., Rafat, Z., & Abollahi, A. (2022) · Current Medical Mycology · doi:10.18502/cmm.7.4.8406 · Cited by 23
Lin, J., Xiao, X., Liang, Y., Zhao, H., Yu, Y., Yuan, P., Lu, S., & Ding, X. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1065962 · Cited by 19
“For example, 93% of Candida isolates showed resistance to fluconazole and 35% Candida isolates were resistant to amphotericin B (Lockhart et al., 2016).”
BackgroundCandida auris in Austria—What Is New and What Is Different
Spettel, K., Kriz, R., Wu, C. C., Achter, L., Schmid, S., Galazka, S., Selitsch, B., Camp, I., Makristathis, A., Lagler, H., et al. (2023) · Journal of Fungi · doi:10.3390/jof9020129 · Cited by 21
“Both genotypical lineages have been associated with invasive infections and high case fatality rates [1].”
BackgroundToepfer, S., Lackner, M., Keniya, M. V., & Monk, B. C. (2023) · Journal of Fungi · doi:10.3390/jof9020168 · Cited by 20
“strains are susceptible to Fluconazole (FLC), Amphotericin B (AMB), and the echinocandins Anidulafungin and Caspofungin [6,7,10] but, compared to JCM 15448T, B11220 exhibits a 4-fold higher minimum inhibitory concentration (MIC) for FLC.”
BackgroundInfluentialChallenges in the diagnosis and treatment of candidemia due to multidrug-resistant Candida auris
Giacobbe, D. R., Mikulska, M., Vena, A., Pilato, V. D., Magnasco, L., Marchese, A. E., & Bassetti, M. (2023) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2023.1061150 · Cited by 20
“local transmission events in outbreak settings (Lockhart et al., 2017; Di Pilato et al., 2021; Salah et al., 2021).”
Lorenzo-Villegas, D. L., Gohil, N. V., Lamo, P., Gurajala, S., Bagiu, I. C., Vulcănescu, D. D., Horhat, F. G., Sorop, V. B., Diaconu, M. M., Sorop, M. I., et al. (2023) · Life · doi:10.3390/life13102099 · Cited by 22
“C. auris , a multidrug-resistant pathogen, causes serious bloodstream and wound infections in hospitalized patients, especially those having breathing tubes, feeding tubes, or central venous catheters [11].”
BackgroundDescription of Candida auris Occurrence in a Tertiary Health Institution in Riyadh, Saudi Arabia
Alshahrani, F. S., Elgujja, A. A., Alsubaie, S., Ezreqat, S., Albarraq, A. M., Barry, M. A., Binkhamis, K. M., & Alabdan, L. I. (2023) · Healthcare · doi:10.3390/healthcare11243150 · Cited by 21
Current Perspectives of Antifungal Therapy: A Special Focus on Candida auris
Arumugam, G., Muthuselvam, M., de Lima, P. M. N., Rajendran, R., & Junqueira, J. C. (2024) · Journal of Fungi · doi:10.3390/jof10060408 · Cited by 22
“[6].”
ResultCandida auris in critically ill patients: Emerging threat in intensive care unit of hospitals
Das, S., Rai, G., Tigga, R. A., Srivastava, S., Singh, P. K., Sharma, R. K., Datt, S., Singh, N. P., & Dar, S. A. (2018) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2018.06.005 · Cited by 24
Crea, F., Codda, G., Orsi, A., Battaglini, A., Giacobbe, D. R., Delfino, E., Ungaro, R., & Marchese, A. E. (2019) · Eurosurveillance · doi:10.2807/1560-7917.es.2019.24.37.1900549 · Cited by 20
Detection of Candida auris Antifungal Drug Resistance Markers Directly from Clinical Skin Swabs
Kordalewska, M., Lee, A., Zhao, Y., & Perlin, D. S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01754-19 · Cited by 20
Ninan, M. M., Sahni, R. D., Chacko, B., Veeraraghavan, B., & Michael, J. S. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.10.018 · Cited by 20
Emerging Microbiology Diagnostics for Transplant Infections: On the Cusp of a Paradigm Shift
Azar, M. M., Gaston, D. C., Kotton, C. N., & Malinis, M. F. (2020) · Transplantation · doi:10.1097/tp.0000000000003123 · Cited by 19
Ayala-Gaytán, J. J., Montoya, A. M., Martínez‐Reséndez, M. F., Guajardo-Lara, C. E., Treviño‐Rangel, R. D. J., Salazar‐Cavazos, L., Llaca-Díaz, J. M., & González, G. M. (2020) · Infection · doi:10.1007/s15010-020-01525-1 · Cited by 21
Carolis, E. D., Marchionni, F., Rosa, M. L., Meis, J. F. G. M., Chowdhary, A., Posteraro, B., & Sanguinetti, M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.645049 · Cited by 19
“7%) of 12 susceptible isolates, as determined by the Sensititre YeastOne (herein used as the reference method) and published tentative echinocandin breakpoints (Lockhart et al., 2017).”
BackgroundMethodSelf-citationGovender, N. P., Todd, J., Nel, J. S., Mer, M., Karstaedt, A., Cohen, C., & GERMS-SA1, F. (2021) · Emerging infectious diseases · doi:10.3201/eid2706.210128 · Cited by 19
Self-citationActivity of rezafungin against Candida auris
Locke, J. B., Andes, D. R., Flanagan, S., Redell, M. A., Ong, V. S., Aram, J. A., Pappas, P. G., Castanheira, M., & Thompson, G. R. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf124 · Cited by 20
Self-citationGülten, E., Çınar, G., Sarıcaoğlu, E. M., Kalkan, İ. A., Yılmaz, A. Z., Saldere, E. H., & Yörük, F. (2025) · Journal of Fungi · doi:10.3390/jof11080552 · Cited by 18
Emerging and re‐emerging fungal threats in Africa
Dangarembizi, R., Wasserman, S. A., & Hoving, J. C. (2022) · Parasite Immunology · doi:10.1111/pim.12953 · Cited by 22
“expansion, partially explaining its insidious spread and sudden global appearance.(112,114,116) Misidentification as Candida haemulonii and”
BackgroundDas, D., HogenEsch, H., & Thangamani, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1123200 · Cited by 18
Potent antifungal properties of gallic acid in Sarcochlamys pulcherrima against Candida auris
Akhtar, N., Mannan, M. A.-U., Pandey, D., Sarkar, A., Sharma, H., Kumar, M., & Ghosh, A. (2023) · Biotechnologia · doi:10.5114/bta.2023.127202 · Cited by 18
Kurakado, S., Matsumoto, Y., & Sugita, T. (2023) · Medical Mycology · doi:10.1093/mmy/myad108 · Cited by 18
Chow, E. W. L., Song, Y., Chen, J., Xu, X., Wang, J., Chen, K., Gao, J., & Wang, Y. (2023) · mBio · doi:10.1128/mbio.02688-23 · Cited by 22
Ettadili, H., & Vural, C. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-01239-0 · Cited by 20
“Indeed, fluconazole resistance in C. auris was associated with different mutations in the ERG11 gene known as amino acid substitutions at some specific positions (e.g., F126T or F126L or V125A in South Africa, Y132F or K143R in India, Y132F in Venezuela) [11, 51, 53, 54].”
Secretion of the fungal toxin candidalysin is dependent on conserved precursor peptide sequences
Müller, R., König, A., Groth, S., Żarnowski, R., Visser, C., Handrianz, T., Maufrais, C., Krüger, T., Himmel, M., Lee, S., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01606-z · Cited by 20
Genome-wide analysis of in vivo-evolved Candida auris reveals multidrug-resistance mechanisms
Chen, X.-F., Zhang, H., Liu, L.-L., Guo, L., Liu, W., Liu, Y., Li, D. S., Zhao, Y., Zhu, R.-Y., Li, Y., et al. (2024) · Mycopathologia · doi:10.1007/s11046-024-00832-7 · Cited by 19
“2_Cand_ auris_B8441_V2) genome was used as the reference genome for read mapping [1].”
Program, C. N. I. S. (2024) · Canada Communicable Disease Report · doi:10.14745/ccdr.v50i06a02 · Cited by 26
“Reported crude mortality for C. auris ranges widely from 15%–60% but is generally similar to other Candida species (57–63).”
BackgroundRhodes, J. L., Jacobs, J. L., Dennis, E. K., Manjari, S. R., Banavali, N. K., Marlow, R., Rokebul, M. A., Chaturvedi, S., & Chaturvedi, V. P. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00911-24 · Cited by 20
“Whole-genome sequencing and variant calling of C. auris 20–34 and 20–32 were performed using the C. auris B8441v2 reference genome (PEKT02000000) (5).”
Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris
Toepfer, S., Keniya, M. V., Lackner, M., & Monk, B. C. (2024) · Journal of Fungi · doi:10.3390/jof10100698 · Cited by 23
“Candidozyma auris (= Candida auris ) has emerged recently as a threat responsible for nosocomial outbreaks across the globe [13,14] and has been recognized as major a global risk by both the CDC and the WHO [1,15–17].”
BackgroundWoodworth, M. H., Dynerman, D., Crawford, E. D., Doernberg, S. B., Ramírez-Àvila, L., Serpa, P. H., Nichols, A. D., Li, L. M., Lyden, A., Tato, C. M., et al. (2019) · Microbial Drug Resistance · doi:10.1089/mdr.2018.0408 · Cited by 19
“Since identification in 2009, it is increasingly recognized as an important cause of invasive disease and nosocomial outbreaks, with high-associated in-hospital mortality of 40–72%.(1) Genomic evaluation of strains from multiple geographic regions suggests simultaneous emergence of distinct geographic clades on three…”
BackgroundMethodResultInfluentialGangadoo, S., Elbourne, A. J., Medvedev, A. E., Cozzolino, D., Truong, Y. B., Crawford, R. J., Wang, P., Truong, V. K., & Chapman, J. (2020) · Coatings · doi:10.3390/coatings10010028 · Cited by 18
Ross, Z. K., & Lorenz, A. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009094 · Cited by 19
“auris clades differ from each other genetically by thousands of single nucleotide polymorphisms (SNPs), yet within each clade, independent clonal expansions typically take place within an outbreak [2].”
BackgroundTits, J., Berman, J. G., Cammue, B. P. A., & Thevissen, K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.617214 · Cited by 21
“, 2020), which is inherently fluconazole-resistant and resistant tomost antifungal drug classes (Lockhart et al., 2017; Ostrowsky et al., 2020).”
BackgroundIbrahim, A., Baron, S. A., Yousfi, H., Hadjadj, L., Lalaoui, R., Morand, S., Rolain, J., & Bittar, F. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04176-8 · Cited by 19
Gisi, U. (2021) · Plant Pathology · doi:10.1111/ppa.13429 · Cited by 26
Liposomal amphotericin B—the future
Hoenigl, M., Lewis, R. E., van de Veerdonk, F. L., Verweij, P. E., & Cornely, O. A. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac353 · Cited by 20
Thermogenic Characterization and Antifungal Susceptibility of Candida auris by Microcalorimetry
Luca, M. D., Koliszak, A., Karbysheva, S., Chowdhary, A., Meis, J. F. G. M., & Trampuž, A. (2019) · Journal of Fungi · doi:10.3390/jof5040103 · Cited by 20
Self-citationAntifungal Activity of Plant Secondary Metabolites on Candida albicans: An Updated Review
Khan, A., Moni, S. S., Ali, M., Mohan, S., Jan, H., Rasool, S., Kamal, M. A., Alshahrani, S., Halawi, M., & Alhazmi, H. A. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467215666220304143332 · Cited by 17
Xue, J., Yue, H., Lu, W., Li, Y., Huang, G., & Fu, Y. V. (2024) · Applied and Environmental Microbiology · doi:10.1128/aem.01025-24 · Cited by 18
“and some display resistance to more than two antifungal agents (8).”
Barbian, H. J., Lie, L., Kittner, A., Harrington, A., Carson, J. S., Frias, M., Slade, D. H., Kim, D. Y., Black, S. R., Parada, J. P., et al. (2025) · Emerging infectious diseases · doi:10.3201/eid3103.241195 · Cited by 19
Candida auris: outbreak fungal pathogen in COVID-19 pandemic: a systematic review and meta-analysis
Lankarani, K. B., Akbari, M., Tabrizi, R., Vali, M., Sekhavati, E., Heydari, S. T., Khodadadi, H., & Ahmadizar, F. (2022) · Iranian Journal of Microbiology · doi:10.18502/ijm.v14i3.9753 · Cited by 22
Sphingolipid diversity in Candida auris: unraveling interclade and drug resistance fingerprints
Ali, B., Kumar, M., Kumar, P., Chauhan, A., Usmani, S. A., Rudramurthy, S. M., Meis, J. F. G. M., Chakrabarti, A., Singh, A., Gaur, N. A., et al. (2024) · FEMS Yeast Research · doi:10.1093/femsyr/foae008 · Cited by 19
“The simultaneous global emergence of distinct clades of Candida auris , along with its resistance to multiple antifungal drugs, has posed a significant challenge for clinicians worldwide (Lockhart et al. 2017 ).”
BackgroundSelf-citationCombatting Fungal Infections: Advances in Antifungal Polymeric Nanomaterials
Schaefer, S., Corrigan, N. A., Brunke, S., Lenardon, M. D., & Boyer, C. A. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00866 · Cited by 19
A Narrative Review of Invasive Candidiasis in the Intensive Care Unit
Noppè, E., Eloff, J. R. P., Keane, S., & Martín‐Loeches, I. (2024) · Therapeutic Advances in Pulmonary and Critical Care Medicine · doi:10.1177/29768675241304684 · Cited by 21
Detection of Candida auris and its antifungal susceptibility: first report from Bangladesh
Dutta, S., Rahman, M. H., Hossain, K. S., & Haq, J. A. (2020) · IMC Journal of Medical Science · doi:10.3329/imcjms.v13i2.45276 · Cited by 20
“auris isolated between 2009 and 2017 were resistant to fluconazole, voriconazole and amphotericin B, respectively [12].”
BackgroundResultOutbreak investigation of Candida auris at a tertiary care hospital in Karachi, Pakistan
Farooqi, J. Q., Soomro, A. S., Baig, M. A., Sajjad, S. F., Hamid, K., Jabeen, K., Naqvi, M., Nasir, N., Roshan, R., Mahmood, S. F., et al. (2020) · Journal of Infection Prevention · doi:10.1177/1757177420935639 · Cited by 21
“Whole genome sequencing was also performed on these 15 isolates and all were found to belong to the same clade with nearly identical strains differing by 2 single-nucleotide polymorphisms, confirming the outbreak (Lockhart et al., 2017).”
BackgroundMethodInfluentialSelf-citationCandida auris – recommendations on infection prevention and control measures in Switzerland
Vuichard‐Gysin, D., Sommerstein, R., Martischang, R., Harbarth, S., Kuster, S. P., Senn, L., & Widmer, A. F. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20297 · Cited by 19
Fan, Y., Wang, Y., & Xu, J. (2020) · Microorganisms · doi:10.3390/microorganisms8111673 · Cited by 17
Schamberger, B., & Plaetzer, K. (2021) · Antibiotics · doi:10.3390/antibiotics10111315 · Cited by 17
Palliyil, S., Mawer, M., Alawfi, S. A., Fogg, L. G., Tan, T. H., Cesare, G. B. D., Walker, L. A., MacCallum, D. M., Porter, A. J., & Munro, C. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01957-21 · Cited by 20
Clinical utility of antifungal susceptibility testing
McCarty, T. P., Luethy, P. M., Baddley, J. W., & Pappas, P. G. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac067 · Cited by 19
Shaban, S., Patel, M., & Ahmad, A. (2022) · International Microbiology · doi:10.1007/s10123-022-00290-5 · Cited by 19
First report of Candida auris in Romania: clinical and molecular aspects
Stanciu, A. M., Florea, D., Surleac, M. D., Paraschiv, S., Oţelea, D., Tălăpan, D., & Popescu, G. A. (2023) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-023-01297-x · Cited by 18
“The isolates included in this study followed the same pattern and were all classified as resistant according to the CDC tentative MIC breakpoints [9, 23].”
ResultHong, H., Ximing, Y., Jinghan, M., Al-Danakh, A., Shujuan, P., Ying, L., Yang, Y., Yuehong, L., & Xingwei, Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1211626 · Cited by 18
Are we ready for the global emergence of multidrug-resistant Candida auris in Taiwan?
Lu, P., Liu, W., Lo, H., Wang, F., Ko, W., Hsueh, P., Ho, M., Liu, C.-E., Chen, Y., Chen, Y., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2017.10.005 · Cited by 19
Understanding the role of host immune responses in invasive candidiasis
Desai, J. V., van de Veerdonk, F. L., & Lionakis, M. S. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4988-5 · Cited by 19
Origin of new emergent Coronavirus and Candida fungal diseases—Terrestrial or cosmic?
Steele, E. J., Gorczynski, R. M., Lindley, R. A., Tokoro, G., Temple, R., & Wickramasinghe, N. C. (2020) · Advances in genetics · doi:10.1016/bs.adgen.2020.04.002 · Cited by 20
“The data demands that there are at least four pre-existing clades ( ≥ 10,000 SNP differences) in an external non-terrestrial source (cometary dust tails) and these came down separately in separate regions and thereafter spread clonally (Lockhart et al., 2017).”
Rodrigues, L. S., Gazara, R. K., Passarelli‐Araujo, H., Valengo, A. E., Pontes, P. V. M., da Fonseca, R. N., de Souza, R. F., Venâncio, T. M., & Dalla-Costa, L. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01535 · Cited by 17
Emerging Antifungal Drug Resistance in Aspergillus fumigatus and Among Other Species of Aspergillus
Toyotome, T., Hagiwara, D., Takahashi, H., Watanabe, A., & Kamei, K. (2018) · Current Fungal Infection Reports · doi:10.1007/s12281-018-0318-9 · Cited by 20
Candida auris skin tropism and antifungal resistance are mediated by carbonic anhydrase Nce103
Phan-Canh, T., Coman, C., Lackner, M., Troppmair, N., Müller, C., Cerbu, D., Seiser, S., Penninger, P., Tsymala, I., Khunweeraphong, N., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02189-z · Cited by 16
“Hence, we hypothesized that proteomics may identify key pathways involved in C. auris MDR traits from differentially abundant proteins (DAPs).”
InfluentialSelf-citationA Comparative Transcriptome Between Anti-drug Sensitive and Resistant Candida auris in China
Zhou, W., Li, X., Lin, Y., Yan, W., Jiang, S., Huang, X., Yang, X., Qiao, D., & Li, N. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.708009 · Cited by 16
“Reliable identification methods involve systems with updated databases and molecular methods, which target the specific sequences of C. auris (Kathuria et al., 2015; Kordalewska et al., 2017; Sexton et al., 2018; Forsberg et al., 2019; Lima et al., 2019; Lone and Ahmad, 2019).”
MethodSalama, E. A., Elgammal, Y., Wijeratne, A., Lanman, N. A., Utturkar, S. M., Farhangian, A., Li, J., Meunier, B., Hazbun, T. R., & Seleem, M. N. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2322649 · Cited by 16
“%) has been reported towards the third class (echinocandins) [10,11].”
BackgroundChauhan, A., Carolus, H., Sofras, D., Kumar, M., Kumar, P., Nair, R., Narayanan, A., Yadav, K., Ali, B., Biriukov, V., et al. (2025) · Molecular Microbiology · doi:10.1111/mmi.15379 · Cited by 16
Deng, Y., Xu, M., Li, S., Bing, J., Zheng, Q., Huang, G., Liao, W., Pan, W., & Tao, L. (2024) · PLOS Pathogens · doi:10.1371/journal.ppat.1012362 · Cited by 16
Candida auris, a singular emergent pathogenic yeast: its resistance and new therapeutic alternatives
Fernandes, L., Ribeiro, R., Henriques, M., & Rodrigues, M. E. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-022-04497-2 · Cited by 17
Identification and Antifungal Drug Susceptibility Pattern of Candida auris in India
Deshkar, S. T., Patil, N., Amberkar, S., Lad, A., Siddiqui, F., & Sharan, S. (2022) · Journal of Global Infectious Diseases · doi:10.4103/jgid.jgid_44_22 · Cited by 16
“[13,17,18,21,23,24] The first echinocandin‐resistant isolates were reported in 2015[13] and then after few reports documenting echinocandin resistance were published.[17,20,24,27] In the present study, 4% (n = 2) isolates were found to be resistant to echinocandin caspofungin.”
BackgroundResultInfluentialZhu, Y., Hager, K. M., Manjari, S. R., Banavali, N. K., Chaturvedi, V. P., & Chaturvedi, S. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.01767-22 · Cited by 17
“We've got to get out”—Strategies of human pathogenic fungi to escape from phagocytes
Sonnberger, J., Kasper, L., Lange, T., Brunke, S., & Hube, B. (2023) · Molecular Microbiology · doi:10.1111/mmi.15149 · Cited by 17
Metadata
- Authors
- Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., Berkow, E. L., Castanheira, M., Magobo, R. E., Jabeen, K., Asghar, R. J., Meis, J. F., Jackson, B., Chiller, T., & Litvintseva, A. P.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Aga Khan University (PK)
- University of Delhi (IN)
- National Health Laboratory Service (ZA)
- Universidade Federal de São Paulo (BR)
- Universidad del Zulia (VE)
- Broad Institute (US)
- JMI Laboratories (US)
- Radboud University Nijmegen (NL)
- ORCID
- Lockhart, Shawn R.
- Vallabhaneni, Snigdha
- Farooqi, Joveria
- Chowdhary, Anuradha
- Govender, Nelesh P.
- Colombo, Arnaldo Lopes
- Cuomo, Christina A.
- Desjardins, Christopher A.
- Berkow, Elizabeth L.
- Castanheira, Mariana
- Magobo, Rindidzani E.
- Jabeen, Kauser
- Asghar, Rana J.
- Meis, Jacques F.
- Jackson, Brendan
- Chiller, Tom
- Litvintseva, Anastasia P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-20
- Volume
- 64
- Issue
- 2
- Pages
- 134-140
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC5215215
- OpenAlex
- W2536287248
- Semantic Scholar
- c8d8e54651d8fb7a7ece68270cd2630d1cd0df39
- Cited by
- 1,662
- References
- 32
- Citations by year
- 2026: 196 · 2025: 194 · 2024: 203 · 2023: 186 · 2022: 160 · 2021: 178 · 2020: 187 · 2019: 152 · 2018: 116 · 2017: 81 · 2016: 5
- FWCI
- 108.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- public-domain
- Locations
- Clinical Infectious Diseases (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U19AI110818)
- United States Agency for International Development (4-338/PAK-US/HEC/2010/932)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida auris, multidrug resistance, antifungal resistance, clonal populations, ERG11 mutations, azole resistance, fluconazole resistance, bloodstream infection, invasive candidiasis, nosocomial infections, risk factors, transmission, whole genome sequencing, antifungal susceptibility
- MeSH terms
- Whole Genome Sequencing, Adolescent, Adult, Aged, Antifungal Agents, Candida, Candidiasis, Child, Child, Preschool, Cytochrome P-450 Enzyme System, Female, Humans, Infant, Infant, Newborn, Male, Microbial Sensitivity Tests, Middle Aged, Mutation, Phylogeny, RNA, Ribosomal, 28S, Global Health, Genome, Fungal, Drug Resistance, Multiple, Polymorphism, Single Nucleotide, DNA, Ribosomal Spacer, Drug Resistance, Fungal, Young Adult, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.